Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$70.27 USD

70.27
5,424,803

+1.80 (2.63%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

by Zacks Equity Research

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Edwards Lifesciences Stock Now

by Zacks Equity Research

Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.

Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Edwards Lifesciences (EW) closed the most recent trading day at $231.46, moving -0.67% from the previous trading session.

Edwards Lifesciences (EW) Stock Moves -0.5%: What You Should Know

by Zacks Equity Research

In the latest trading session, Edwards Lifesciences (EW) closed at $234.61, marking a -0.5% move from the previous day.

Edwards (EW) Rides on Innovation Despite Regulatory Issues

by Zacks Equity Research

Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.

Tracey Ryniec headshot

Top Stock Picks for the Week of Dec 23, 2019

by Tracey Ryniec

Tracey Ryniec takes a look at two Zacks Rank #1 (Strong Buy) stocks.

Zacks Market Edge Highlights: Edwards Lifesciences, Sony, Alibaba, State Street and Exxon

by Zacks Equity Research

Zacks Market Edge Highlights: Edwards Lifesciences, Sony, Alibaba, State Street and Exxon

The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals

Tracey Ryniec headshot

Investing Outlook for 2020: Recession or Not?

by Tracey Ryniec

Some stock market bears have been waiting for a US recession for four years. Is 2020 the year they will finally be right or will they have to throw in the towel and join the bull's party?

Sejuti Banerjea headshot

Uber Is Formally into the Staffing Business

by Sejuti Banerjea

Uber Works makes Uber more like the technology platform it claims to be and less the ride-hailing service that we recognize it as.

    Edwards Lifesciences (EW) Upgraded to Strong Buy: Here's Why

    by Zacks Equity Research

    Edwards Lifesciences (EW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Tirthankar Chakraborty headshot

    New Strong Buy Stocks for December 19th

    by Tirthankar Chakraborty

    Here are 3 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

    Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    Edwards Lifesciences (EW) closed at $235.63 in the latest trading session, marking a -0.96% move from the prior day.

    Here's Why You Should Hold on to Allscripts Stock for Now

    by Zacks Equity Research

    Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

    Here's Why You Should Bet on Integer Holdings Stock Now

    by Zacks Equity Research

    Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

    Here's Why You Should Invest in Cardinal Health Stock Now

    by Zacks Equity Research

    Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

    NextGen Healthcare Boosts Patient Care With CHC Strategies

    by Zacks Equity Research

    NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.

    Here's Why You Should Retain NextGen Healthcare for Now

    by Zacks Equity Research

    NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

    Here's Why You Should Retain Wright Medical Stock For Now

    by Zacks Equity Research

    Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.

    Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth

    by Zacks Equity Research

    Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.

    Here's Why You Should Hold on to Cerner (CERN) Stock Now

    by Zacks Equity Research

    Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

    NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?

    by Zacks Equity Research

    NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    Here's Why You Should Retain Nevro (NVRO) Stock for Now

    by Zacks Equity Research

    Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

    Patterson Companies (PDCO) Q2 Earnings Surpass Estimates

    by Zacks Equity Research

    Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.